[1] XU JY, CHENG WW.Application effect of hepatoprotective drugs in patients with hepatitis viral infectious diseases[J]. Chinese Journal of Drug Abuse Prevention(中国药物滥用防治杂志), 2021, 27(4): 603-605. [2] LU LG, CAI XB, WANG JS, et al.Guidelines for the management of cholestatic liver disease(2021)[J]. Journal of Clinical Hepatobiliary Diseases(临床肝胆病杂志), 2022, 38(1): 62-69. [3] CAI X, QIN RW, LIU YQ, et al.Study on the mechanism of Guizhi improving ANIT-induced intrahepatic cholestasis in a rat model by regulating FXR pathway[J]. China Journal of Traditional Chinese Medicine(中国中药杂志), 2019, 44(12): 2594-2599. [4] CHEN CW, CHENG J, DOU XG, et al.Consensus on the diagnosis and treatment of cholestatic liver disease (2015)[J]. Journal of Clinical Hepatobiliary Diseases(临床肝胆病杂志), 2015, 31(12): 1989-1999. [5] LI YX, LI XP, GU J, et al.Study on the protective mechanism of Tibetan medicine twenty-five flavors Songshi pills on cholestatic liver injury rats based on FXR signaling pathway[J]. China Journal of Traditional Chinese Medicine(中国中药杂志), 2020, 45(21): 5273-5279. [6] LI T, CHIANG JYL.Bile acid signaling in metabolic disease and drug therapy[J]. Pharmacological Reviews, 2014, 66(4): 948-983. [7] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China,Volume I(中华人民共和国药典一部)[M]. Beijing: China Medical Science Press, 2020. [8] XU DC.The Hundred Kinds of Shennong’s Materia Medica(神农本草经百种录)[M]. BeiJing: Xueyuan Publishing House, 1956. [9] YAO XM, ZHOU XJ, ZHOU YY.Research progress on chemical constituents and pharmacological effects of Cistanche deserticola[J]. Acta Chinese Medicine and Pharmacology(中医药学报), 2021, 49(2): 93-97. [10] ZHI YJ, ZHEN YQ, TIAN W, et al.Research progress on chemical constituents and pharmacological effects of Cistanche deserticola and predictive analysis of quality markers (Q-Marker)[J]. Chinese Herbal Medicine(中草药), 2021, 52(9): 2758-2767 . [11] ZHANG SL, YOU SP, ZHAO J, et al.Study on the protective effect of Cistanche deserticola phenethyl glycoside liposome on BSA-induced liver fibrosis in rats[J]. Cancer, Distortion, Mutation(癌变·畸变·突变), 2019, 31(6): 428-433. [12] WANG FJ, TU PF ZENG KW, et al. Study on the protective effect of total glucosides of Cistanche deserticola on alcoholic liver injury in mice[J]. Chinese Journal of Pharmacy(药学学报), 2021, 56(9): 2528-2535. [13] RUDICH N, ZAMIR G, PAPPO O, et al.Focal liver necrosis appears early after partial hepatectomy and is dependent on T cells and antigen delivery from the gut[J]. Liver International, 2010, 29(8): 1273-1284. [14] Ofliver EAF.EASL clinical practice guidelines: management of cholestatic liver diseases[J]. Journal of Hepatology, 2009, 51: 237-367. [15] TIAN C, ZHANG T, WANG L, et al.The hepatoprotective effect and chemical constituents of total iridoids and xanthones extracted from Swertia mussotii Franch[J]. Journal of Ethnopharmacology, 2014, 154(1): 259-266. [16] XUE HY, JIAO CY, YAO J.Research status of pharmacological effects of total glucosides of Cistanche deserticola[J]. Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2018, 34(4): 486-488. [17] ÖSTERREICHER CH, TRAUNER M.Xenobiotic-induced liver injury and fibrosis[J]. Expert Opinion on Drug Metabolism & Toxicology, 2012, 8(5): 571-580. [18] ZHOU F, XU HM.Effects of emodin on the expression of P-gp in rats with intrahepatic cholestasis[J]. China Journal of Traditional Chinese Medicine(中国中药杂志), 2010, 35(7): 908-911. [19 ZHOU YF, ZHONG GY, ZHU JX, et al. Discussion on the protective effect and mechanism of the extract of Tibetan medicine “Yajima” (bare stem golden waist) on ANIT-induced intrahepatic cholestasis in mice[J]. China Journal of Traditional Chinese Medicine(中国中药杂志), 2019, 44(5): 1058-1063. [20] CAO XX, GAO YQ, ZHANG WH, et al.Cholestasis morbidity rate in first-hospitalized patients with chronic liver disease in Shanghai[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2015, 23(8): 569-573. |